USA-based biopharma firm Sevion Therapeutics (OTCQB: SVON) has entered into a collaboration agreement with CNA Development, an affiliate of Janssen Pharmaceuticals, to discover antibodies using Sevion’s spatially addressed library platform.
The collaboration, facilitated by Johnson & Johnson’s (NYSE: JNJ) J&J Innovation center in California, will include discovery of antibodies against multiple targets in several therapeutic areas.
Sevion and Janssen will jointly conduct research on antibodies discovered by Sevion, and Janssen will have an option to an exclusive license to develop, manufacture, and commercialize candidates resulting from the collaboration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze